Brandon W Higgs

Summary

Affiliation: MedImmune Vaccines
Country: USA

Publications

  1. doi request reprint Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
    Brandon W Higgs
    Translational Sciences, MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    Ann Rheum Dis 70:2029-36. 2011
  2. doi request reprint Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients
    Brandon W Higgs
    Translational Sciences, MedImmune, LLC, Gaithersburg, MD 20878, USA
    Int J Rheum Dis 15:25-35. 2012
  3. doi request reprint Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus
    Yihong Yao
    MedImmune, Gaithersburg, Maryland 20878, USA
    Arthritis Rheum 60:1785-96. 2009
  4. pmc Genomic signatures characterize leukocyte infiltration in myositis muscles
    Wei Zhu
    Translational Sciences, MedImmune, LLC, Gaithersburg, MD 20878, USA
    BMC Med Genomics 5:53. 2012
  5. pmc Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus
    Yihong Yao
    MedImmune, Translational Sciences, One MedImmune Way, Gaithersburg, MD 20878, USA
    Arthritis Res Ther 12:S6. 2010
  6. pmc Altered expression of insulin receptor isoforms in breast cancer
    Jiaqi Huang
    MedImmune, LLC, Gaithersburg, Maryland, United States of America
    PLoS ONE 6:e26177. 2011
  7. doi request reprint A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
    Brandon W Higgs
    MedImmune, LLC, Gaithersburg, Maryland, USA
    Ann Rheum Dis 73:256-62. 2014
  8. doi request reprint A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children
    Wei Zhu
    MedImmune, Translational Sciences, Gaithersburg, MD 20878, USA
    Vaccine 28:2865-76. 2010
  9. pmc Type I interferon: potential therapeutic target for psoriasis?
    Yihong Yao
    MedImmune, Inc, Gaithersburg, Maryland, United States of America
    PLoS ONE 3:e2737. 2008
  10. doi request reprint The plasma cell signature in autoimmune disease
    Katie Streicher
    MedImmune, Gaithersburg, Maryland
    Arthritis Rheumatol 66:173-84. 2014

Collaborators

Detail Information

Publications10

  1. doi request reprint Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
    Brandon W Higgs
    Translational Sciences, MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    Ann Rheum Dis 70:2029-36. 2011
    ....
  2. doi request reprint Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients
    Brandon W Higgs
    Translational Sciences, MedImmune, LLC, Gaithersburg, MD 20878, USA
    Int J Rheum Dis 15:25-35. 2012
    ....
  3. doi request reprint Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus
    Yihong Yao
    MedImmune, Gaithersburg, Maryland 20878, USA
    Arthritis Rheum 60:1785-96. 2009
    ..e., granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-10 (IL-10), tumor necrosis factor alpha (TNFalpha), and IL-1beta, in SLE...
  4. pmc Genomic signatures characterize leukocyte infiltration in myositis muscles
    Wei Zhu
    Translational Sciences, MedImmune, LLC, Gaithersburg, MD 20878, USA
    BMC Med Genomics 5:53. 2012
    ....
  5. pmc Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus
    Yihong Yao
    MedImmune, Translational Sciences, One MedImmune Way, Gaithersburg, MD 20878, USA
    Arthritis Res Ther 12:S6. 2010
    ....
  6. pmc Altered expression of insulin receptor isoforms in breast cancer
    Jiaqi Huang
    MedImmune, LLC, Gaithersburg, Maryland, United States of America
    PLoS ONE 6:e26177. 2011
    ....
  7. doi request reprint A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
    Brandon W Higgs
    MedImmune, LLC, Gaithersburg, Maryland, USA
    Ann Rheum Dis 73:256-62. 2014
    ....
  8. doi request reprint A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children
    Wei Zhu
    MedImmune, Translational Sciences, Gaithersburg, MD 20878, USA
    Vaccine 28:2865-76. 2010
    ....
  9. pmc Type I interferon: potential therapeutic target for psoriasis?
    Yihong Yao
    MedImmune, Inc, Gaithersburg, Maryland, United States of America
    PLoS ONE 3:e2737. 2008
    ..To better understand the pathogenesis of this disease and identify potential mediators, we used whole genome array analysis to profile paired lesional and nonlesional psoriatic skin and skin from healthy donors...
  10. doi request reprint The plasma cell signature in autoimmune disease
    Katie Streicher
    MedImmune, Gaithersburg, Maryland
    Arthritis Rheumatol 66:173-84. 2014
    ..We undertook this study to investigate the prevalence of PCs and their relationship to known pathogenic pathways to increase our understanding of the role of PCs in disease progression and treatment response...